PRELUDE CAPITAL MANAGEMENT, LLC - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 119 filers reported holding LYELL IMMUNOPHARMA INC in Q2 2024. The put-call ratio across all filers is 2.88 and the average weighting 0.9%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q1 2024$56,428
+66.2%
25,304
+44.6%
0.00%
+50.0%
Q4 2023$33,958
-16.3%
17,504
+37.2%
0.00%
-33.3%
Q2 2023$40,558
-44.6%
12,754
-58.9%
0.00%
-25.0%
Q1 2023$73,16031,0000.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q2 2024
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$69,963,29235.72%
Orland Properties Ltd 15,093,969$52,376,07227.91%
Foresite Capital Management IV, LLC 10,000,000$34,700,00014.82%
MIC Capital Management UK LLP 3,060,569$10,620,1742.10%
Alphabet Inc. 5,865,125$20,351,9841.18%
HSG Holding Ltd 3,045,997$10,569,6101.07%
Artal Group S.A. 700,000$2,4290.14%
Eagle Health Investments LP 100,000$347,0000.08%
Virtus ETF Advisers LLC 39,345$136,5270.07%
BBR PARTNERS, LLC 164,041$569,2220.06%
View complete list of LYELL IMMUNOPHARMA INC shareholders